Owlet Inc (OWLT)

NYSEHealth CareMedical - DevicesSnapshot 2026-10-23

$4.10-1.20%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Owlet Inc’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	33.48M
EPS	—	-0.04
FY 2026 · Annual
Revenue	$118M–$122M	119.76M
EPS	—	-0.24
EBITDA	$10.75M–$12.75Mnon-GAAP	—
Gross margin	53%–55%	—
FY 2027 · Annual
Revenue	—	144.18M
EPS	—	0.003

What the Thesis Depends On

4 published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Achieve adjusted EBITDA of $7M to $9M in 2026	Adjusted EBITDA is expected to grow to $7 to $9 million.	Improving	Adjusted EBITDA falls below $1.25 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Adjusted EBITDA improved from a loss of $1.5 million in 2026-Q1 to a positive $2.9 million in 2026-Q2 excluding tariff refunds, with full-year guidance raised from $7-$9 million to $10.75-$12.75 million reflecting a one-time tariff refund. The trajectory shows delivering progress toward the adjusted EBITDA target. Delivery assessment Oct 24, 2026
Manage debt and share buybacks prudently	A supporting condition in Owlet Inc's published investment case. The stated target is Maintain manageable debt levels and execute buybacks without harming liquidity.	Intact	Debt levels rise unsustainably or buybacks impair liquidity	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Achieve gross margins of 50% to 52% in 2026	The company plans to improve gross margins to 50% to 52%.	Intact	Gross margin falls below 48% in FY26	Gross margin: 64.44% FY2026-Q2; GAAP. Published target: 50% to 52%. Target period is not explicitly aligned with this observation. Source published Aug 14, 202664.441163 percent · calculatedSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 489e9057-5183-4746-8672-c0433023abb5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Gross margin improved from 51.3% in 2025-Q2 to 64.4% in 2026-Q2 including a $3.5 million tariff refund; excluding the refund, margin was 54.0%, up 270 basis points year-over-year. The trajectory is on track with management's stated gross margin target of 53% to 55% for 2026. Delivery assessment Oct 24, 2026
Achieve revenue of $118M to $122M in 2026	A primary condition in Owlet Inc's published investment case. The stated target is >= $118 million total revenue.	Intact	Total revenue falls below $103 million in FY26	Revenue: $33.865M FY2026-Q2; GAAP. Published target: >= $118 million total revenue. Target period is not explicitly aligned with this observation. Source published Aug 14, 202633,865,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 489e9057-5183-4746-8672-c0433023abb5. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 3 of last 3 quarters. Revenue grew from $26.1 million in 2025-Q2 to $33.9 million in 2026-Q2, a 29.9% increase year-over-year. Full-year 2026 revenue guidance remains at $118 to $122 million, representing 12% to 15% growth over 2025. The trajectory is delivering on management's revenue growth target. Delivery assessment Oct 24, 2026

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenueUnavailable

$0.15B → Unavailable · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	$145,378,800	2 / 5
2026-07-25	Unavailable	$145,378,800	2 / 5
2026-07-26	Unavailable	$145,378,800	2 / 5
2026-07-27	Unavailable	Unavailable	2 / 4
2026-07-28	Unavailable	$145,378,800	2 / 5
2026-07-29	Unavailable	$145,378,800	2 / 5
2026-07-30	Unavailable	$145,378,800	2 / 5
2026-07-31	Unavailable	Unavailable	2 / 4
2026-08-01	Unavailable	Unavailable	2 / 4
2026-08-02	Unavailable	$145,378,800	2 / 5
2026-08-03	Unavailable	$145,378,800	2 / 5
2026-08-04	Unavailable	$145,378,800	2 / 5
2026-08-05	Unavailable	Unavailable	2 / 3
2026-08-06	Unavailable	$145,378,800	2 / 5
2026-08-07	Unavailable	Unavailable	2 / 3
2026-08-08	Unavailable	$145,378,800	2 / 5
2026-08-09	Unavailable	Unavailable	2 / 3
2026-08-10	Unavailable	$145,378,800	2 / 5
2026-08-12	Unavailable	Unavailable	2 / 3
2026-08-13	Unavailable	Unavailable	2 / 3
2026-08-14	Unavailable	Unavailable	2 / 3
2026-08-15	Unavailable	Unavailable	2 / 3
2026-08-16	Unavailable	Unavailable	2 / 3
2026-08-17	Unavailable	Unavailable	2 / 3
2026-08-18	Unavailable	Unavailable	2 / 3
2026-08-19	Unavailable	Unavailable	2 / 3
2026-08-20	Unavailable	Unavailable	2 / 4
2026-08-21	Unavailable	Unavailable	2 / 4
2026-08-22	Unavailable	Unavailable	2 / 4
2026-08-23	Unavailable	Unavailable	2 / 4
2026-08-24	Unavailable	Unavailable	2 / 4
2026-08-25	Unavailable	Unavailable	2 / 4
2026-08-26	Unavailable	Unavailable	2 / 4
2026-08-27	Unavailable	Unavailable	2 / 4
2026-08-28	Unavailable	Unavailable	2 / 4
2026-08-29	Unavailable	Unavailable	2 / 4
2026-08-30	Unavailable	Unavailable	2 / 4
2026-08-31	Unavailable	Unavailable	2 / 4
2026-09-01	Unavailable	Unavailable	2 / 4
2026-09-02	Unavailable	Unavailable	2 / 4
2026-09-03	Unavailable	Unavailable	2 / 4
2026-09-04	Unavailable	Unavailable	2 / 4
2026-09-05	Unavailable	Unavailable	2 / 4
2026-09-06	Unavailable	Unavailable	2 / 4
2026-09-07	Unavailable	Unavailable	2 / 4
2026-09-08	Unavailable	Unavailable	2 / 4
2026-09-09	Unavailable	Unavailable	2 / 4
2026-09-10	Unavailable	Unavailable	2 / 4
2026-09-11	Unavailable	Unavailable	2 / 4
2026-09-12	Unavailable	Unavailable	2 / 4
2026-09-13	Unavailable	Unavailable	2 / 4
2026-09-14	Unavailable	Unavailable	2 / 4
2026-09-15	Unavailable	Unavailable	2 / 4
2026-09-16	Unavailable	Unavailable	2 / 4
2026-09-17	Unavailable	Unavailable	2 / 4
2026-09-18	Unavailable	Unavailable	2 / 4
2026-09-19	Unavailable	Unavailable	2 / 4
2026-09-20	Unavailable	Unavailable	2 / 4
2026-09-21	Unavailable	Unavailable	2 / 4
2026-09-22	Unavailable	Unavailable	2 / 4
2026-09-23	Unavailable	Unavailable	2 / 4
2026-09-24	Unavailable	Unavailable	2 / 4
2026-09-25	Unavailable	Unavailable	2 / 4
2026-09-26	Unavailable	Unavailable	2 / 4
2026-09-27	Unavailable	Unavailable	2 / 4
2026-09-28	Unavailable	Unavailable	2 / 4
2026-09-29	Unavailable	Unavailable	2 / 4
2026-09-30	Unavailable	Unavailable	2 / 4
2026-10-01	Unavailable	Unavailable	2 / 4
2026-10-02	Unavailable	Unavailable	2 / 4
2026-10-03	Unavailable	Unavailable	2 / 4
2026-10-04	Unavailable	Unavailable	2 / 4
2026-10-05	Unavailable	Unavailable	2 / 4
2026-10-06	Unavailable	Unavailable	2 / 4
2026-10-07	Unavailable	Unavailable	2 / 4
2026-10-08	Unavailable	Unavailable	2 / 4
2026-10-09	Unavailable	Unavailable	2 / 4
2026-10-10	Unavailable	Unavailable	2 / 4
2026-10-11	Unavailable	Unavailable	2 / 4
2026-10-12	Unavailable	Unavailable	2 / 4
2026-10-13	Unavailable	Unavailable	2 / 4
2026-10-14	Unavailable	Unavailable	2 / 4
2026-10-15	Unavailable	Unavailable	2 / 4
2026-10-16	Unavailable	Unavailable	2 / 4
2026-10-17	Unavailable	Unavailable	2 / 4
2026-10-18	Unavailable	Unavailable	2 / 4
2026-10-19	Unavailable	Unavailable	2 / 4
2026-10-20	Unavailable	Unavailable	2 / 4
2026-10-21	Unavailable	Unavailable	2 / 4
2026-10-22	Unavailable	Unavailable	2 / 4
2026-10-23	Unavailable	Unavailable	2 / 4
2026-10-24	Unavailable	Unavailable	2 / 4

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	5	0	0
2026-06-01	5	0	0
2026-07-01	5	0	0
2026-08-01	5	0	0
2026-09-01	5	0	0
2026-10-01	5	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Achieve adjusted EBITDA of $7M to $9M in 2026Direct metric needs a verified mapping
Manage debt and share buybacks prudentlyQualitative condition
Achieve gross margins of 50% to 52% in 2026Gross margin: 64.44%
Achieve revenue of $118M to $122M in 2026Revenue: $33.865M

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

4 of 4 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.3%Typical daily move · historical

Downside history

-75.2%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Owlet Inc outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a high-risk growth business with improving operating performance, rather than a proven durable compounder. The long-term thesis is intact, with revenue growth on track and profitability progress visible, though the evidence is limited and confidence is medium.

What's priced into Owlet Inc

The valuation evidence describes OWLT as cheap versus peers, while also showing a 39% premium versus peers and a negative expectations gap, which points to a mixed comparison. The model has low confidence, and no valuation fragility flags fired, so what the market assumes remains uncertain.

What the fundamentals likely do

Near term, revenue guidance remains at 12% to 15% growth for 2026, and second-quarter revenue rose 29.9% year over year. Gross margin was 54.0% excluding the tariff refund, while adjusted EBITDA improved to positive $2.9 million excluding refunds; the full-year EBITDA target includes a one-time tariff refund. The near-term miss watch is quiet, but smaller-company risk and a deep prior miss warrant attention, and a guidance cut would be a meaningful setback.

What Owlet Inc hinges on

The multi-year view depends on continued revenue growth and improved margins translating into sustained profitability, rather than results relying on one-time tariff refunds. Near term, reaffirmed guidance and execution against the EBITDA target matter; weakening jobs data could weigh on cyclical healthcare names, while continued strong results from sector bellwethers could support the sector backdrop.